Literature DB >> 7655763

Double-blind, placebo-controlled, pharmacokinetic and -dynamic studies with 2 new formulations of piracetam (infusion and sirup) under hypoxia in man.

B Saletu1, G Hitzenberger, J Grünberger, P Anderer, G Zyhlarz, L Linzmayer, H Rameis.   

Abstract

In a double-blind, placebo-controlled study, pharmacokinetics and pharmacodynamics of 12 g piracetam in 2 different formulations were investigated utilizing blood gas analysis, EEG mapping and psychometry under a transient, reversible, hypoxic hypoxidosis. The latter was induced by a fixed gas combination of 9.8% oxygen (O2) and 90.2% nitrogen (N2, found in 6,000 m altitude), which was inhaled for 23 minutes under normobraic conditions by 18 healthy volunteers. They received after an adaptation session randomized at weekly intervals 12 g piracetam i.v. (250 ml infusion over 30 minutes), 12 g piracetam p.o. (60 ml sirup) and placebo. Blood levels were determined by means of an HPLC at the hours 0, 1, 2, 4, 6, 8 and 24. The 2 formulations showed a very similar time-course, with slightly higher blood levels in the 1st hour after the intravenous than oral administration, and vice versa thereafter. The elimination half-life was 4.3 hours for both formulations, the area under the curve and the clearance value were also almost identical. Evaluation of blood gases, EEG mapping and psychometry were carried out at 0, 2, 4, 6 and 8 hours post-drug. Blood gas analysis demonstrated a drop in SaO2 from 99 to 73 and 70%, in PO2 from 100 to 35 and 33 mmHg, in PCO2 from 36 to 31 and 31 mmHg in the 14th and 23rd minute of inhalation, respectively. pH increased from 7.43 to 7.48 in the respective minutes, while base excess and standard bicarbonate remained stable. EEG mapping exhibited under hypoxia a marked increase of total power, mostly due to an augmentation of delta/theta, and a decrease of alpha activity, which reflects deterioration of vigilance. Both piracetam preparations significantly attenuated this vigilance decrement, with 12 g piracetam i.v. showing its encephalotropic peak effects in the earlier hours, 12 g piracetam sirup in the later hours. At the behavioral level, hypoxic hypoxidosis induced a deterioration of the noo- and thymopsyche, which was mitigated by both piracetam preparations, mostly in the 6th hour. Both formulations were well tolerated.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7655763

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN: 0946-1965            Impact factor:   1.366


  9 in total

Review 1.  Cognition enhancers in age-related cognitive decline.

Authors:  W J Riedel; J Jolles
Journal:  Drugs Aging       Date:  1996-04       Impact factor: 3.923

2.  Pharmacokinetic Study of Piracetam in Focal Cerebral Ischemic Rats.

Authors:  Pankaj Paliwal; Debabrata Dash; Sairam Krishnamurthy
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-04       Impact factor: 2.441

3.  The metabolic enhancer piracetam ameliorates the impairment of mitochondrial function and neurite outgrowth induced by beta-amyloid peptide.

Authors:  C Kurz; I Ungerer; U Lipka; S Kirr; T Schütt; A Eckert; K Leuner; W E Müller
Journal:  Br J Pharmacol       Date:  2010-03-09       Impact factor: 8.739

4.  Piracetam improves mitochondrial dysfunction following oxidative stress.

Authors:  Uta Keil; Isabel Scherping; Susanne Hauptmann; Katin Schuessel; Anne Eckert; Walter E Müller
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

5.  Improved mitochondrial function in brain aging and Alzheimer disease - the new mechanism of action of the old metabolic enhancer piracetam.

Authors:  Kristina Leuner; Christopher Kurz; Giorgio Guidetti; Jean-Marc Orgogozo; Walter E Müller
Journal:  Front Neurosci       Date:  2010-09-07       Impact factor: 4.677

6.  Reductions in qEEG slowing over 1 year and after treatment with Cerebrolysin in patients with moderate-severe traumatic brain injury.

Authors:  X Antón Alvarez; Carolina Sampedro; Jesús Figueroa; Iván Tellado; Andrés González; Manuel García-Fantini; Ramón Cacabelos; Dafin Muresanu; Herbert Moessler
Journal:  J Neural Transm (Vienna)       Date:  2008-02-14       Impact factor: 3.575

7.  Effect of piracetam on the cognitive performance of patients undergoing coronary bypass surgery: A meta-analysis.

Authors:  Yu Fang; Zhandong Qiu; Wentao Hu; Jia Yang; Xiyan Yi; Liangjiang Huang; Suming Zhang
Journal:  Exp Ther Med       Date:  2013-11-26       Impact factor: 2.447

8.  Enhanced Neuroplasticity by the Metabolic Enhancer Piracetam Associated with Improved Mitochondrial Dynamics and Altered Permeability Transition Pore Function.

Authors:  Carola Stockburger; Davide Miano; Thea Pallas; Kristina Friedland; Walter E Müller
Journal:  Neural Plast       Date:  2016-09-26       Impact factor: 3.599

9.  Effect of Dietary Nitrate Supplementation on Sleep in Chronic Obstructive Pulmonary Disease Patients.

Authors:  Jonathan P Wisor; Nils Henrik Holmedahl; Ingvild West Saxvig; Odd-Magne Fjeldstad; Eddie Weitzberg; Janne Grønli; Harald Kåre Engan
Journal:  Nat Sci Sleep       Date:  2021-03-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.